Tom Chappie
Senior Principal Scientist & Research Fellow Pfizer
Tom Chappie is a Research Fellow at Pfizer and an experienced medicinal chemist focused on drug discovery and RNA-targeted therapeutics. He brings more than 25 years of experience across neuroscience and metabolic disease research, with a track record of leading multidisciplinary teams that have advanced multiple small molecules into clinical development. His work includes identifying and assessing novel next-generation targets, developing hit-identification strategies, and exploring small-molecule approaches to RNA biology.
Seminars
Thursday 12th November 2026
Panel Discussion: Establishing RNA-Targeted Small Molecules as a Generalizable Drug Modality
3:30 pm
- Which disease areas beyond rare genetic indications – respiratory, immunology, and other high-prevalence settings – are genuinely within reach, and what makes a target there tractable?
- What new chemotypes, mechanisms, and platforms are needed to expand beyond risdiplam- and branaplam-like analogs and a handful of target classes – and how far should we extend the one validated mechanism class versus seek genuinely new ones?
- What translational, safety, and selectivity evidence is required to convince the field that RNA targeting is a generalizable modality rather than a niche?
